What is Lifesci Capital’s Estimate for OLMA FY2025 Earnings?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Research analysts at Lifesci Capital issued their FY2025 earnings per share estimates for Olema Pharmaceuticals in a research report issued on Wednesday, November 13th. Lifesci Capital analyst S. Slutsky anticipates that the company will post earnings of ($2.12) per share for the year. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.32) per share.

OLMA has been the subject of several other reports. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Wednesday. JPMorgan Chase & Co. decreased their price objective on Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a report on Wednesday, August 7th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Olema Pharmaceuticals has a consensus rating of “Buy” and an average price target of $27.00.

Olema Pharmaceuticals Price Performance

Olema Pharmaceuticals stock opened at $9.17 on Friday. The business has a 50 day moving average of $12.00 and a 200-day moving average of $11.97. The company has a market capitalization of $525.42 million, a P/E ratio of -4.19 and a beta of 2.02. Olema Pharmaceuticals has a 1 year low of $8.51 and a 1 year high of $17.10.

Hedge Funds Weigh In On Olema Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Ensign Peak Advisors Inc raised its position in shares of Olema Pharmaceuticals by 6.1% in the 2nd quarter. Ensign Peak Advisors Inc now owns 14,849 shares of the company’s stock worth $161,000 after acquiring an additional 850 shares in the last quarter. California State Teachers Retirement System increased its holdings in Olema Pharmaceuticals by 3.4% in the first quarter. California State Teachers Retirement System now owns 34,695 shares of the company’s stock worth $393,000 after purchasing an additional 1,132 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Olema Pharmaceuticals by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 26,251 shares of the company’s stock valued at $298,000 after buying an additional 1,486 shares during the period. ClariVest Asset Management LLC boosted its holdings in shares of Olema Pharmaceuticals by 3.1% during the 2nd quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company’s stock worth $683,000 after buying an additional 1,881 shares in the last quarter. Finally, EP Wealth Advisors LLC grew its position in shares of Olema Pharmaceuticals by 5.2% during the 3rd quarter. EP Wealth Advisors LLC now owns 48,655 shares of the company’s stock worth $581,000 after buying an additional 2,407 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.